AS703569 Phase I in Patients With Solid Tumours

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
EMD Serono
ClinicalTrials.gov Identifier:
NCT00391521
First received: October 20, 2006
Last updated: January 29, 2014
Last verified: January 2014

October 20, 2006
January 29, 2014
August 2006
June 2010   (final data collection date for primary outcome measure)
Number and proportion of subjects experiencing: at least a Dose-Limiting Toxicity (DLT) in each cohort during the first cycle. [ Time Frame: Undefined ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00391521 on ClinicalTrials.gov Archive Site
  • Plasma and urine PK parameters of AS703569, genetic markers and potential markers of clinical and biological response. [ Time Frame: Undefined ] [ Designated as safety issue: Yes ]
  • Number and proportion of subjects with Progressive Disease as assessed at the end of every other cycle. [ Time Frame: Undefined ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Not Provided
 
AS703569 Phase I in Patients With Solid Tumours
A Phase I Multicenter, Open-Label, Dose Escalation Trial of AS703569 Given Orally to Subjects With Solid Tumours

This is a Phase I trial. Some specific protocol information is proprietary and is not publicly available at this time. Full information will be provided to trial participants.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Solid Tumors
  • Drug: AS703569
    Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle
    Other Names:
    • MSC1992371A
    • Aurora kinase inhibitor
  • Drug: AS703569
    Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle
    Other Names:
    • MSC1992371A
    • Aurora kinase inhibitor
  • Drug: AS703569
    Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle
    Other Names:
    • MSC1992371A
    • Aurora kinase inhibitor
  • Active Comparator: 1
    Regimen 1
    Intervention: Drug: AS703569
  • Active Comparator: 2
    Regimen 2
    Intervention: Drug: AS703569
  • Active Comparator: 3
    Regimen 3
    Intervention: Drug: AS703569
Mita M, Gordon M, Rejeb N, Gianella-Borradori A, Jego V, Mita A, Sarantopoulos J, Sankhala K, Mendelson D. A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors. Target Oncol. 2013 Jul 6. [Epub ahead of print]

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
104
June 2010
June 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Histopathologically confirmed locally advanced or metastatic solid tumour that is either refractory after standard of care therapy for the disease or for which standard of care therapy is not reliably effective or has a cancer for which no standard therapy exists
  2. Age greater than or equal to 18 years
  3. Has read and understands the informed consent form and is willing and able to give informed consent, and subject authorization under Health Insurance Portability and Accountability Act (HIPAA). Fully understands requirements of the study and willing to comply with all study visits and assessments
  4. Subjects and their partners must be willing to avoid pregnancy during the study and until 1 month after the last study drug administration. Males with female partners of childbearing potential and female subjects of childbearing potential must therefore be willing to use adequate contraception such as, intra uterine device, diaphragm, or condom, for the duration of the study. For the purposes of this study, childbearing potential is defined as: "All female subjects unless they are post- menopausal for at least two years, are surgically sterile or sexually inactive"
  5. Negative serum pregnancy test at the screening visit for women of childbearing potential

Exclusion Criteria:

  1. Bone marrow impairment as evidenced by Hb < 9.0 g/dl, ANC < 1.5x 109/L, platelets < 75 x 109/L. Subjects may be transfused.
  2. Renal impairment as evidenced by serum creatinine > 1.5 x ULN (upper limit of normal), and/or calculated creatinine clearance < 60 ml/min
  3. Liver function abnormality as defined by total bilirubin > 1.5 ULN, or AST or ALT > 2.5x ULN at screening; for subjects with liver involvement AST or ALT > 5x ULN at screening
  4. INR (blood coagulation) > 1.5 x ULN for subjects not on therapeutic doses of coumadin
  5. History of CNS metastases, unless subject has been previously treated for CNS metastases, is stable by CT scan without evidence of cerebral edema, and has no requirements for corticosteroids or anticonvulsants
  6. History of difficulty swallowing, malabsorption or other chronic gastro- intestinal disease or conditions that may hamper compliance and/or absorption of the tested product
  7. Eastern Cooperative Oncology Group Performance Status (ECOG PS) > 2
  8. Known HIV, hepatitis C, or hepatitis B positivity
  9. Has received chemotherapy, immunotherapy, hormonal therapy, biologic therapy, or any other anticancer therapy or surgical intervention within 28 Days of Day 1 of study drug treatment (6 weeks for nitrosureas or mitomycin C), and must have fully recovered
  10. Has received extensive prior radiotherapy on more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation
  11. Has received any investigational agent within 28 days of Day 1
  12. Has history of any other significant medical disease or intervention including major gastric or small bowel surgery or has a psychiatric condition that might impair the subjects well-being or preclude full participation in the study
  13. Is a pregnant or nursing female
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00391521
26865
Not Provided
EMD Serono
EMD Serono
Not Provided
Study Director: Narmyn Rejeb, MD Merck Serono S.A., Geneva
EMD Serono
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP